- Home
- ZION vs CORT Comparison
ZION vs CORT Comparison
Compare ZION & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ZION | CORT |
|---|---|---|
| Founded | 1873 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.4B | 3.7B |
| IPO Year | N/A | 2001 |
Fundamental Metrics
Financial Performance| Metric | ZION | CORT |
|---|---|---|
| Price | $58.30 | $35.71 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 20 | 6 |
| Target Price | $63.40 | ★ $105.20 |
| AVG Volume (30 Days) | ★ 1.9M | 1.7M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | ★ 3.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.82 |
| Revenue | N/A | ★ $761,407,000.00 |
| Revenue This Year | $8.48 | $30.63 |
| Revenue Next Year | $4.67 | $31.61 |
| P/E Ratio | ★ $10.32 | $43.02 |
| Revenue Growth | N/A | ★ 12.79 |
| 52 Week Low | $39.32 | $28.66 |
| 52 Week High | $66.18 | $117.33 |
Technical Indicators
Market Signals| Indicator | ZION | CORT |
|---|---|---|
| Relative Strength Index (RSI) | 43.85 | 38.36 |
| Support Level | $57.89 | $33.53 |
| Resistance Level | $59.17 | $41.92 |
| Average True Range (ATR) | 2.12 | 2.55 |
| MACD | -0.53 | 0.39 |
| Stochastic Oscillator | 35.51 | 58.57 |
Price Performance
Historical ComparisonAbout ZION Zions Bancorporation N.A.
Zions Bancorp is a US regional bank with around $90 billion in total assets as of Sept. 30, 2025. Headquartered in Salt Lake City, Utah, Zions' branch network is in the Western and Southwestern United States and includes seven affiliate banks in these markets. The bank has a heavy focus on small and midsize commercial banking.
About CORT Corcept Therapeutics Incorporated
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol. The company's compounds are being evaluated in clinical trials as potential treatments for a variety of serious disorders - hypercortisolism, advanced ovarian cancer, prostate cancer, ALS, and MASH.